Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ELOVL1-22 is an inhibitor of ELOVL fatty acid elongase 1 (ELOVL1).1 It reduces lysohexacosanoylphosphatidylcholine (LPC(C26:0)) synthesis in HEK293 cells (IC50 = 400 pM), a marker of ELOVL1 inhibition, and is selective for ELOVL1 over ELOVL4, -6, and -7 (IC50s = >50 µM for all), as well as a panel of 34 receptors at 10 µM. ELOVL1-22 (1-32 mg/kg) reduces blood and CNS levels of LPC(C26:0) in an Abcd1-/- mouse model of adrenoleukodystrophy (ALD), a neurodegenerative disease characterized by rapid inflammatory demyelination of the CNS.
WARNING This product is not for human or veterinary use.
1. Discovery of novel, orally bioavailable pyrimidine ether-